The most notable malaria vaccine is RTS,S/AS01 (Mosquirix), developed by GlaxoSmithKline. This vaccine targets Plasmodium falciparum and is designed for use in children aged 5 months to 17 months. Clinical trials have shown that Mosquirix can reduce the number of malaria cases by about 30% in this age group. The World Health Organization (WHO) has recommended the vaccine for broader use in areas with moderate to high transmission of the disease.
